Glucocorticoid Induced Osteoporosis

Glucocorticoid Induced Osteoporosis (GIO)

M. Shams, M.D.

Endocrine and Metabolism Research Center

Shiraz University of Medical Sciences

Glucocorticoid Induced Osteoporosis (GIO)

Glucocorticoids (GC) are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders.
Osteoporosis is a well-known adverse effect of glucocorticoid.
GIO is the most common cause of secondary osteoporosis.
It is estimated that >10% of patients who receive long-term glucocorticoid treatment are diagnosed with a fracture.
How often do we use Glucocorticoids?

- More than 10 million Americans receive pharmacologic doses of glucocorticoids each

year. US: 1% (Fardet 2015)

- 3% in 50 years and over, 5.2% in 80 and over (Kanis 2004)

- Global Longitudinal Study of Osteoporosis in Women (GLOW),

in 10 countries: 4.6% of 60,393 postmenopausal women used GC.

Glucocorticoid Induced Osteoporosis